13-Valent Pneumococcal Polysaccharide Conjugate Vaccine not checked
CanSino Biologics Inc. · PCV13i
FollowEvery change as it happens, and a Monday email
Trials
2 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)”In the company’s words, NCT07017777 on ClinicalTrials.gov
- Tested for
- Pneumococcal Infections, Streptococcal Infections, Bacterial Infections, Streptococcus Pneumoniae Infection
- Main trialPhase 3
- “This is a Phase 3 randomized, observation-blinded, active-controlled, parallel-group clinical trial designed to evaluate the immunogenicity, safety, and functional antibody response of the experimental vaccine versus the control vaccine in healthy Thailand infants vaccinated at a 2+1 schedule (2 months, 4 months and 12-15 months). The trial will enroll approximately 600 healthy infants aged 2 months (at least 6 weeks) who will be randomly assigned in a 1:1 ratio to receive either the experimental or control vaccine, with 100 in each group (200 in total) randomized to subgroups and subject to…”In the company’s words, NCT07017777 on ClinicalTrials.gov
- Other names
- PCV13i
Other drugs for Pneumococcal Infections
- 20vPCVSanofi · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- PG4Pfizer · Phase 3
- Pneumococcal conjugate vaccinePfizer · Phase 3
- PrevnarPfizer · Phase 3
- 20vPCV licensed vaccineSanofi · Phase 3
Coming up2
- 24 NovPhase 1/2 trial completes · ClinicalTrials.gov
- 15 Feb 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 15 Feb 2027 | A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) | |
| Phase 1/2Recruiting | 24 Nov 2026 | Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) | |
| Phase 3Completed | 30 Mar 2022 | Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) | |
| Phase 1Completed | 23 Jun 2021 | Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026